# FDA Audit Management Process

Document Number|Title|Effective|Owner
---------------|-------------------------------------|----|-----
QP-0020|FDA Audit Management Process|9/1/2021|/s/ Ben West

1.  **Purpose**

 This document defines the policies and procedures for managing FDA
 inspections conducted at company facilities. All employees shall
 cooperate with the FDA to the fullest extent required by law and as
 established in relevant FDA regulations.

2.  **Scope**

 This procedure applies to all employees, subcontractors, and others
 who manage and otherwise participate in FDA inspections

3.  **General**

3.1.  **Definitions** – N/A

3.2.  **Responsibilities**

 **Quality** – Quality is responsible for leading the FDA inspection
 and ensuring informational requests fulfilled with the appropriate
 documentation and records. Quality is responsible for maintaining any
 FDA inspection records and any follow-up activities

 **All Employees** – All employees are responsible for participating
 and cooperating with a FDA inspection to the extent specified in this
 procedure.

3.3.  **Equipment and Materials** – N/A

3.4.  **Safety Precautions** – N/A

3.5.  **Training Requirement** – All employees associated with medical
     devices shall be trained to this procedure.

3.6.  **Record Management** – All inspection records, FDA Establishment
     Inspection Reports (EIR), and FDA Form 483 are maintained by the
     Quality Department.

3.7.  **Reference Documents and Materials**

 **21 CFR 820** – FDA Quality System Regulations

 **FDA Inspection Guides** – Guide to Inspections of Medical Device
 Manufacturers

4.  **Procedure**

 Although regulation allows for unscheduled FDA inspections,
 inspections are generally scheduled to ensure appropriate records and
 staff are available. The Quality Management Representative will lead
 FDA Audit activities. In the event the Management Representative is
 unavailable; the Deputy Management Representative will be substituted.

4.1.  **Audit Preparation**

 In preparation for a FDA inspection, the following activities shall be
 completed:

-   Review Quality Systems and Procedures

-   Review any previous FDA Form 483’s.

-   Assign responsibilities to the team and ensure each individual
     understands their role (i.e. greeter, notetaker, runner, etc.)

-   General overview of code of conduct, room assignments, etc.

4.2  **During the Audit**

 During the FDA Inspection, all employees shall cooperate with the FDA
 to the fullest extent required by law and as established in relevant
 FDA regulations. Upon arrival, the FDA Inspector shall be politely
 asked to show his/her credentials and to disclose the intent of their
 visit. Once credentials are verified, the inspector shall be escorted
 to a conference room. FDA Inspector questions and inquiries will be
 directed to the employee with the appropriate expertise. Answers shall
 be as short and direct as possible to satisfy only the question asked
 by the inspector. Employees are directed to be honest and readily
 admit if they do not know the answer, do not ramble or go on tangents.

 Employees should never sign any FDA documents without knowledge of
 Management Representative and/or General Council. This is to protect
 the employee from unknowingly signing documents that can subject them
 or the company to liability.

4.2.1  **Excluded Documentation and Records**

 Documents that the FDA may not inspect, unless voluntarily provided to
 the FDA include:

-   Internal and Supplier Quality Audits (only records necessary to
     demonstrate activities are completed)

-   Management Review (only records necessary to demonstrate activities
     are completed)

-   Financial Data

-   Sales, Pricing, and Customer Data (other than traceability records)

-   Personnel Data (other than records necessary to demonstrate
     competency and qualifications)

4.2.2  **Record Requests**

 All records and procedures requested by the FDA inspector shall be
 provide as physical documents. These shall be printed in duplicate
 from a workstation removed from the auditor. One copy shall be
 provided to the FDA inspector; the second copy shall be provided to
 the notetaker or Management Rep.

4.3.  **Audit Completion**

 Following the FDA Inspection, the Management Representative shall
 correspond with the FDA as necessary to obtain an Establishment
 Inspection Report and resolve any 483’s that were reported.

5.      Revision History

This document  QP-0020_R1_FDA_Audit_Management_Process.md
is subject to revision. Only the latest approved version should be used.

Major revisions are enumerated below.
The "latest" and only official version is found in the github document management system governs all QMS activity.

REV #|Doc ID|Effective Date|Description of Change
-----|------|--------------|---------------------
01   | QP-0020|12/17/2014|Initial Release
